Skip to content
Fashion, Medical Health Aged Care

Monash expert: How the summer heat could be ruining your sunscreen and cosmetics

Monash University 2 mins read

A Monash University expert is *available to comment on how high temperatures could be impacting the effectiveness of your sunscreen and other cosmetics, and how you can safeguard them.  

 

Dr Laurence Orlando, Pharmacy and Pharmaceutical Sciences Education, Faculty of Pharmacy and Pharmaceutical Sciences

Contact: +61 450 501 248 (Media Manager Teju Hari Krishna) or [email protected]  

*Note: Dr Orlando is available only for recorded interviews

  • How does high temperature impact different cosmetics? 
  • How should you store them during summer? 
  • Can your cosmetics actually "go bad"? And what would happen if you used these cosmetics? 

The following can be attributed to Dr Orlando:

“High temperatures can significantly impact both cosmetics and sunscreens, compromising their effectiveness and usability. Chemical sunscreens, which rely on active ingredients like avobenzone and oxybenzone, are particularly heat-sensitive. 

 

“Prolonged exposure to high temperatures—such as inside cars or beach bags—can degrade their UV-filtering abilities, reduce efficacy, and cause physical changes like separation, runniness, or a grainy texture. This instability can lead to uneven application and reduced sun protection, necessitating more frequent reapplication, especially during intense heat or sweating. 

 

“Cosmetics, too, are vulnerable to heat. Creams and lotions may separate, lipsticks and balms can melt, and natural or water-based products may foster bacterial growth. Heat can also oxidize essential oils and active ingredients, altering their scent or causing irritation. 

 

“To prevent these issues, it’s essential to store sunscreens and cosmetics in cool, shaded areas, use insulated bags or ice packs when outdoors, and monitor products for changes in texture, smell, or appearance. It is recommended to use mineral sunscreens, with heat-stable ingredients like zinc oxide or titanium dioxide, as a reliable alternative during extreme heat, as they maintain their stability and provide effective UV protection.” 

For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or [email protected]. For more Monash media stories visit our news & events site.

More from this category

  • Fashion, Music
  • 08/12/2025
  • 11:54
Canturi Jewels

Troye Sivan wears CANTURI to NGV Gala

Troye Sivan Shines in CANTURI Jewellery at the NGV Gala in Melbourne Melbourne, Australia – Internationally acclaimed Australian singer, songwriter, and actor Troye Sivan…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.